Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Fenghuang Zhan

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
Address4104 Outpatient Circle
Mail Slot # 508
Little Rock AR 72205
Phone501-686-8511
ORCID ORCID Icon0000-0001-5417-2973 Additional info
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    I01BX006235     (ZHAN, FENGHUANG)Oct 1, 2024 - Sep 30, 2028
    NIH
    Characterize Drug Resistance in Multiple Myeloma
    Role: Principal Investigator
    6702-25     (ZHAN, FENGHUANG)Jul 1, 2024 - Jun 30, 2027
    Leukemia & Lymphoma Society
    Toward improvement of BCMA/CST6-CAR-T therapy to target both myeloma cells and bone resorption
    Role: Principal Investigator
    P20GM152281     (EOFF, ROBERT L)Mar 5, 2024 - Dec 31, 2028
    NIH
    Center for Molecular Interactions in Cancer (CMIC)
    Role: Co-Investigator
    1U54CA272691-01A1     (ZHAN, FENGHUANG)Sep 1, 2023 - Aug 31, 2027
    NIH/Nat. Cancer Institute - Pass Through: Baylor College of Medicine
    U54 - Administrative Core
    Role: Principal Investigator
    U54CA272691     (ZHAN, FENGHUANG)Sep 1, 2023 - Aug 31, 2027
    NIH/Nat. Cancer Institute - Pass Through: Baylor College of Medicine
    Project 1 – Prevention of MGUS progression to MM by modulating the bone marrow microenvironment
    Role: Principal Investigator
         (Fenghuang Zhan)Apr 23, 2021 - Apr 22, 2022
    The Paula and Rodger Riney Foundation
    Targeting NEK2 Enables Immune Checkpoint Blockade in High-Risk/Relapsed Myeloma
    Role Description: Goals of this study 1. Determine the sensitivity of primary tumor cells to immune checkpoint blockade in different molecular myeloma subtypes. 2. Define, characterize and evaluate the therapeutic potency, and selectivity and toxicity of a NEK2 degrader CRBN-PROTAC-NEK2i. 3. Determine the therapeutic effects of CRBN-PROTAC-NEK2i and optimize combinations with standard myeloma drugs and immune checkpoint blockade. 4. Apply to the FDA for an Investigational New Drug for the CRBN-PROTAC-NEK2i in collaboration with a pharmaceutical company for clinical trials in aggressive and relapsed myeloma patients.
    Role: Principal Investigator
    R01CA236814     (ZHAN, FENGHUANG)Jun 1, 2020 - May 31, 2025
    NIH
    Novel NEK2 signaling pathways in myeloma progression
    Role: Principal Investigator
    W81XWH1910500     (ZHAN, FENGHUANG)Apr 15, 2020 - Nov 14, 2023
    US Department of Defense
    CD24 Tumor-Initiating Cell as a Novel Therapeutic Target in Myeloma
    Role: Principal Investigator
    R01CA151354     (ZHAN, FENGHUANG)Jan 1, 2020 - Jun 30, 2023
    NIH/Nat. Cancer Institute - Pass Through: Medical College of Wisconsin
    Biological Validation of Candidate Myeloma Driver Genes
    Role: Principal Investigator
    R01CA152105     (ZHAN, FENGHUANG)Jul 1, 2010 - May 31, 2016
    NIH
    NEK2 Over-expression Causes Drug Resistance in Myeloma
    Role: Principal Investigator
    R21CA143887     (ZHAN, FENGHUANG)Jul 1, 2010 - Jun 30, 2013
    NIH
    Retinoid Based Treatment Approaches to Target the Myeloma Stem Cell
    Role: Principal Investigator
    R01CA115399     (TRICOT, GUIDO J.)Jul 13, 2006 - Apr 30, 2014
    NIH
    Gene expression profiling vs MRD assessment in Myeloma
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Qin L, Moreno Rueda LY, Ray U, Mahmud I, Tan L, Lorenzi PL, Liu S, Lin H, Mery DE, Zhan F, Shaughnessy JD, Yi Q, Acevedo Calado MJ, Wang H, Manasanch EE, Lee HC, Patel KK, Kuiatse I, Symer DE, Orlowski RZ. Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma. Blood. 2025 May 29; 145(22):2614-2629. PMID: 39912779.
      View in: PubMed
    2. Mohan Lal B, Alzubi M, Alrawabdeh J, Shaughnessy JD, Zhan F, Siegel ER, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Al Hadidi S. Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma. Blood Adv. 2025 May 13; 9(9):2155-2158. PMID: 39938011.
      View in: PubMed
    3. Mohan Lal B, Pandey T, Alzubi M, Alrawabdeh J, Shaughnessy J, Zhan F, Siegel ER, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Al Hadidi S. Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience. Bone Marrow Transplant. 2025 Apr 17. PMID: 40246944.
      View in: PubMed
    4. Gai D, Caviness PC, Lazarenko OP, Chen JF, Randolph CE, Zhang Z, Cheng Y, Sun F, Xu H, Blackburn ML, Tricot G, Shaughnessy JD, Chen JR, Zhan F. Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption. Cancers (Basel). 2025 Feb 27; 17(5). PMID: 40075680.
      View in: PubMed
    5. Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Smith R, Panozzo S, Alapat D, Tricot G, Shaughnessy J, Zhan F, Sawyer J, Siegel ER, Barlogie B, van Rhee F, Zangari M. Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma. Blood Adv. 2025 Feb 25; 9(4):950-953. PMID: 39786380.
      View in: PubMed
    6. Moreno Rueda LY, Wang H, Akagi K, Dang M, Vora A, Qin L, Lee HC, Patel KK, Lin P, Mery DE, Zhan F, Shaughnessy JD, Yi Q, Song Y, Jiang B, Gillison ML, Thomas SK, Weber DM, Diao L, Wang J, Kuiatse I, Manasanch EE, Symer DE, Orlowski RZ. Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets. Cell Rep Med. 2025 Feb 18; 6(2):101925. PMID: 39855192.
      View in: PubMed
    7. Young K, Shi WY, Xu-Monette Z, Jia Y, Tzankov A, Go H, Li L, Ponzoni M, Wang Y, Zhai Q, Perry A, Wang S, Wang X, Chiu A, Xu M, Visco C, Dybkaer K, Withers H, Long M, Yuan A, Miao Y, Li J, Macias E, Shuai W, Wang B, Bhagat G, Zu Y, Pan Z, Choi W, Montes-Moreno S, Chen W, van Krieken JH, M?ller M, Zhan F, Parsons B, Zhang S, Hsi E, Sohani A, Abramson J, Ferreri A, Xu B, Li Y. Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma. Res Sq. 2025 Jan 06. PMID: 39866884.
      View in: PubMed
    8. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, Xu H, Johnson S, Guo W, Bailey C, Ashby C, Bauer MA, Hadidi SA, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024 11 06; 14(1):194. PMID: 39505839.
      View in: PubMed
    9. Patel TH, Bachu R, Shrivastava T, Alrawabdeh J, Alzubi M, Hastings J, Dean H, Schinke C, Thanendrarajan S, Zangari M, Tricot G, Zhan F, Shaughnessy JD, van Rhee F, Al Hadidi S. Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Clin Hematol Int. 2024; 6(3):54-60. PMID: 39345654.
      View in: PubMed
    10. Xia J, Zhao H, Edmondson JL, Koss B, Zhan F. Role of NEK2 in tumorigenesis and tumor progression. Trends Mol Med. 2025 Jan; 31(1):79-93. PMID: 39181803.
      View in: PubMed
    11. Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Tricot G, Shaughnessy J, Zhan F, Sawyer J, Siegel ER, Zangari M, Barlogie B, van Rhee F. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2024 Nov; 99(11):2222-2224. PMID: 39109821.
      View in: PubMed
    12. Xian M, Wang Q, Xiao L, Zhong L, Xiong W, Ye L, Su P, Zhang C, Li Y, Orlowski RZ, Zhan F, Ganguly S, Zu Y, Qian J, Yi Q. Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis. Nat Commun. 2024 Jul 09; 15(1):5767. PMID: 38982045.
      View in: PubMed
    13. Gai D, Caviness PC, Lazarenko OP, Chen JF, Randolph CE, Zhang Z, Cheng Y, Sun F, Xu H, Blackburn ML, Tricot G, Shaughnessy JD, Chen JR, Zhan F. Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influx. Res Sq. 2024 May 06. PMID: 38766009.
      View in: PubMed
    14. Guo W, Strouse C, Mery D, Siegel ER, Munshi MN, Ashby TC, Cheng Y, Sun F, Wanchai V, Zhang Z, Bailey C, Alapat DV, Peng H, Al Hadidi S, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation. Cancers (Basel). 2024 Mar 11; 16(6). PMID: 38539451.
      View in: PubMed
    15. Li JR, Arsang-Jang S, Cheng Y, Sun F, D'Souza A, Dhakal B, Hari P, Huang Q, Auer P, Li Y, Urrutia R, Zhan F, Shaughnessy JD, Janz S, Dong J, Cheng C. Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. Blood Cancer J. 2024 03 06; 14(1):38. PMID: 38443358.
      View in: PubMed
    16. McCrury M, Swafford K, Shuttleworth SL, Mehdi SH, Acharya B, Saha D, Naceanceno K, Byrum SD, Storey AJ, Xu YZ, Doshier C, Patel V, Post GR, De Loose A, Rodriguez A, Shultz LD, Zhan F, Yoon D, Frett B, Kendrick S. Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Mol Cancer Ther. 2024 Mar 04; 23(3):316-329. PMID: 37816504.
      View in: PubMed
    17. Caviness PC, Lazarenko OP, Blackburn ML, Chen JF, Randolph CE, Zabaleta J, Zhan F, Chen JR. Phenolic acids prevent sex-steroid deficiency-induced bone loss and bone marrow adipogenesis in mice. J Nutr Biochem. 2024 05; 127:109601. PMID: 38367948.
      View in: PubMed
    18. Guo W, Zhan Y, Mery D, Siegel ER, Sun F, Cheng Y, Ashby TC, Zhang Z, Bailey C, Alapat DV, Peng H, Hadidi SA, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood Cancer J. 2024 02 14; 14(1):30. PMID: 38355688.
      View in: PubMed
    19. Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Bailey C, Smith R, Panozzo S, Alapat D, Cottler-Fox M, Tricot G, Shaughnessy JD, Zhan F, Sawyer J, Barlogie B, Zangari M, van Rhee F. Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood Adv. 2024 02 13; 8(3):703-707. PMID: 38052037.
      View in: PubMed
    20. Mao X, Yan W, Mery D, Liu J, Fan H, Xu J, Xu Y, Sui W, Deng S, Zou D, Du C, Yi S, van Rhee F, Barlogie B, Shaughnessy JD, Anderson KC, Zhan F, Qiu L, An G. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma. Am J Hematol. 2024 04; 99(4):523-533. PMID: 38247315.
      View in: PubMed
    21. Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD, Zhan F. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19; 15(1):615. PMID: 38242888.
      View in: PubMed
    22. Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, Xu H, Gai D, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest. 2024 01 02; 134(1). PMID: 37883186.
      View in: PubMed
    23. Zhang Z, Zhan F. Type 2 Cystatins and Their Roles in the Regulation of Human Immune Response and Cancer Progression. Cancers (Basel). 2023 Nov 10; 15(22). PMID: 38001623.
      View in: PubMed
    24. Strouse C, Mott SL, Smith BJ, Magalhaes-Silverman M, Farooq U, Zhan F, Jethava Y, Tricot G. Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients. Bone Marrow Transplant. 2024 01; 59(1):128-130. PMID: 37816907.
      View in: PubMed
    25. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD, Zhan F. High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma. Cell Rep Med. 2023 10 17; 4(10):101214. PMID: 37794587.
      View in: PubMed
    26. Mazahreh F, Mazahreh L, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023 Jul 11; 7(13):3069-3074. PMID: 36857755.
      View in: PubMed
    27. Caviness PC, Gai D, Lazarenko OP, Blackburn ML, Zhan F, Chen JR. Decreased bone resorption in Ezh2 myeloid cell conditional knockout mouse model. FASEB J. 2023 07; 37(7):e23019. PMID: 37272906.
      View in: PubMed
    28. Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023 06 29; 16(1):70. PMID: 37386588.
      View in: PubMed
    29. Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023 08 15; 129(16):2491-2498. PMID: 37282609.
      View in: PubMed
    30. Bloedjes TA, de Wilde G, Khan GH, Ashby TC, Shaughnessy JD, Zhan F, Houtkooper RH, Bende RJ, van Noesel CJM, Spaargaren M, Guikema JEJ. AKT supports the metabolic fitness of multiple myeloma cells by?restricting FOXO activity. Blood Adv. 2023 05 09; 7(9):1697-1712. PMID: 36322819.
      View in: PubMed
    31. Xu L, Wang Y, Wang G, Guo S, Yu D, Feng Q, Hu K, Chen G, Li B, Xu Z, Jia X, Lu Y, Zhang H, Gao X, Chang S, Wang H, Wu X, Song D, Yang G, Zhu H, Zhou J, Zhan F, Zhu W, Shi J. Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma. Leukemia. 2023 07; 37(7):1576-1579. PMID: 37157015.
      View in: PubMed
    32. Abu Za'nouneh FJ, Ababneh O, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Variability of definition of high-risk multiple myeloma across phase III clinical trials. EJHaem. 2023 May; 4(2):454-458. PMID: 37206288.
      View in: PubMed
    33. Roy Choudhury S, Byrum SD, Alkam D, Ashby C, Zhan F, Tackett AJ, Van Rhee F. Expression of integrin ?-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics. Clin Epigenetics. 2023 02 04; 15(1):18. PMID: 36737807.
      View in: PubMed
    34. Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, Peng B, Garg TK, Schinke C, Thanendrarajan S, Zangari M, Chen F, Barlogie B, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J Clin Invest. 2022 09 15; 132(18). PMID: 35881476.
      View in: PubMed
    35. Eliason S, Hong L, Sweat Y, Chalkley C, Cao H, Liu Q, Qi H, Xu H, Zhan F, Amendt BA. Extracellular vesicle expansion of PMIS-miR-210 expression inhibits colorectal tumour growth via apoptosis and an XIST/NME1 regulatory mechanism. Clin Transl Med. 2022 09; 12(9):e1037. PMID: 36116139.
      View in: PubMed
    36. Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Tricot G, van Rhee F, Al Hadidi S. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA Netw Open. 2022 08 01; 5(8):e2228877. PMID: 36018590.
      View in: PubMed
    37. Lin J, Huang D, Xu H, Zhan F, Tan X. Macrophages: A communication network linking Porphyromonas gingivalis infection and associated systemic diseases. Front Immunol. 2022; 13:952040. PMID: 35967399.
      View in: PubMed
    38. Cheng Y, Sun F, Thornton K, Jing X, Dong J, Yun G, Pisano M, Zhan F, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, Hari P, Janz S. FOXM1 regulates glycolysis and energy production in multiple myeloma. Oncogene. 2022 08; 41(32):3899-3911. PMID: 35794249.
      View in: PubMed
    39. Roy Choudhury S, Ashby C, Zhan F, van Rhee F. Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients. Cancers (Basel). 2021 Dec 17; 13(24). PMID: 34944968.
      View in: PubMed
    40. Sun F, Cheng Y, Riordan JD, Dupuy A, Dubois W, Pisano M, Dong J, Mock B, Zhan F, Hari P, Janz S. WDR26 and MTF2 are therapeutic targets in multiple myeloma. J Hematol Oncol. 2021 12 07; 14(1):203. PMID: 34876184.
      View in: PubMed
    41. Li C, Xia J, Franqui-Machin R, Chen F, He Y, Ashby TC, Teng F, Xu H, Liu D, Gai D, Johnson SK, van Rhee F, Janz S, Shaughnessy JD, Tricot G, Frech I, Zhan F. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. J Clin Invest. 2021 07 15; 131(14). PMID: 34061780.
      View in: PubMed
    42. Gu C, Wang W, Tang X, Xu T, Zhang Y, Guo M, Wei R, Wang Y, Jurczyszyn A, Janz S, Beksac M, Zhan F, Seckinger A, Hose D, Pan J, Yang Y. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Mol Cancer. 2021 06 05; 20(1):84. PMID: 34090465.
      View in: PubMed
    43. Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Front Immunol. 2021; 12:667054. PMID: 34149703.
      View in: PubMed
    44. Schinke CD, Bird JT, Qu P, Yaccoby S, Lyzogubov VV, Shelton R, Ling W, Boyle EM, Deshpande S, Byrum SD, Washam C, Mackintosh S, Stephens O, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Barlogie B, van Rhee F, Walker BA. PHF19 inhibition as a therapeutic target in multiple myeloma. Curr Res Transl Med. 2021 07; 69(3):103290. PMID: 33894670.
      View in: PubMed
    45. Jiang F, Tang X, Tang C, Hua Z, Ke M, Wang C, Zhao J, Gao S, Jurczyszyn A, Janz S, Beksac M, Zhan F, Gu C, Yang Y. HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. J Hematol Oncol. 2021 04 01; 14(1):54. PMID: 33794982.
      View in: PubMed
    46. Li C, Wendlandt EB, Darbro B, Xu H, Thomas GS, Tricot G, Chen F, Shaughnessy JD, Zhan F. Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression. Cancers (Basel). 2021 Jan 29; 13(3). PMID: 33572851.
      View in: PubMed
    47. Boyle EM, Deshpande S, Tytarenko R, Ashby C, Wang Y, Bauer MA, Johnson SK, Wardell CP, Thanendrarajan S, Zangari M, Facon T, Dumontet C, Barlogie B, Arbini A, Rustad EH, Maura F, Landgren O, Zhan F, van Rhee F, Schinke C, Davies FE, Morgan GJ, Walker BA. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat Commun. 2021 01 12; 12(1):293. PMID: 33436579.
      View in: PubMed
    48. Chen JR, Zhao H, Wankhade UD, Chintapalli SV, Li C, Gai D, Shankar K, Zhan F, Lazarenko OP. GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice. Commun Biol. 2021 01 08; 4(1):53. PMID: 33420329.
      View in: PubMed
    49. Deshpande S, Tytarenko RG, Wang Y, Boyle EM, Ashby C, Schinke CD, Thanendrarajan S, Zangari M, Zhan F, Davies FE, Morgan GJ, van Rhee F, Walker BA. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. Eur J Haematol. 2021 Feb; 106(2):230-240. PMID: 33107092.
      View in: PubMed
    50. Gu C, Lu T, Wang W, Shao M, Wei R, Guo M, Li R, Qiao L, Hu Y, Zhan F, Seckinger A, Hose D, Yang Y. RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma. Leukemia. 2021 06; 35(6):1803-1807. PMID: 32901100.
      View in: PubMed
    51. Xu J, Tan HB, Zhang YJ, Tang DY, Zhan F, Li HY, Chen ZZ, Xu ZG. Catalyst-Free One-Pot Synthesis of Densely Substituted Pyrazole-Pyrazines as Anti-Colorectal Cancer Agents. Sci Rep. 2020 06 09; 10(1):9281. PMID: 32518332.
      View in: PubMed
    52. Gao M, Bai H, Jethava Y, Wu Y, Zhu Y, Yang Y, Xia J, Cao H, Franqui-Machin R, Nadiminti K, Thomas GS, Salama ME, Altevogt P, Bishop G, Tomasson M, Janz S, Shi J, Chen L, Frech I, Tricot G, Zhan F. Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. J Natl Cancer Inst. 2020 05 01; 112(5):507-515. PMID: 31406992.
      View in: PubMed
    53. Yu T, Du C, Ma X, Sui W, Yu Z, Liu L, Zhao L, Li Z, Xu J, Wei X, Zhou W, Deng S, Zou D, An G, Tai YT, Tricot G, Anderson KC, Qiu L, Zhan F, Hao M. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. Mol Cancer Res. 2020 07; 18(7):1063-1073. PMID: 32312841.
      View in: PubMed
    54. Xia J, He Y, Meng B, Chen S, Zhang J, Wu X, Zhu Y, Shen Y, Feng X, Guan Y, Kuang C, Guo J, Lei Q, Wu Y, An G, Li G, Qiu L, Zhan F, Zhou W. NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma. Mol Oncol. 2020 04; 14(4):763-778. PMID: 31955515.
      View in: PubMed
    55. Li Z, Liu L, Du C, Yu Z, Yang Y, Xu J, Wei X, Zhan F, Lai Y, Qiu L, Hao M. Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma. Cancer Gene Ther. 2020 12; 27(12):869-877. PMID: 31988477.
      View in: PubMed
    56. Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S. Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer. 2019 12 20; 19(1):1238. PMID: 31862002.
      View in: PubMed
    57. Wu C, Zhang L, Brockman QR, Zhan F, Chen L. Chimeric antigen receptor T cell therapies for multiple myeloma. J Hematol Oncol. 2019 11 21; 12(1):120. PMID: 31752943.
      View in: PubMed
    58. Wang Y, Huang J, Li B, Xue H, Tricot G, Hu L, Xu Z, Sun X, Chang S, Gao L, Tao Y, Xu H, Xie Y, Xiao W, Yu D, Kong Y, Chen G, Sun X, Lian F, Zhang N, Wu X, Mao Z, Zhan F, Zhu W, Shi J. A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression. Cancer Res. 2020 02 01; 80(3):536-548. PMID: 31732653.
      View in: PubMed
    59. Yan Y, Mao X, Liu J, Fan H, Du C, Li Z, Yi S, Xu Y, Lv R, Liu W, Deng S, Sui W, Wang Q, Zou D, Wang J, Cheng T, Zhan F, Tai YT, Yuan C, Du X, Qiu L, Anderson KC, An G. The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv. 2019 10 08; 3(19):2895-2904. PMID: 31594763.
      View in: PubMed
    60. Kong Y, Hu L, Lu K, Wang Y, Xie Y, Gao L, Yang G, Xie B, He W, Chen G, Wu H, Wu X, Zhan F, Shi J. Ferroportin downregulation promotes cell proliferation by modulating the Nrf2-miR-17-5p axis in multiple myeloma. Cell Death Dis. 2019 08 19; 10(9):624. PMID: 31423010.
      View in: PubMed
    61. Tong J, Xu X, Zhang Z, Ma C, Xiang R, Liu J, Xu W, Wu C, Li J, Zhan F, Wu Y, Yan H. Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy. Haematologica. 2020 06; 105(6):1630-1640. PMID: 31289203.
      View in: PubMed
    62. Sun F, Cheng Y, Walsh SA, Acevedo MR, Jing X, Han SS, Pisano MD, Tomasson MH, Lichtenstein AK, Zhan F, Hari P, Janz S. Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma. Haematologica. 2020 03; 105(3):e111-e115. PMID: 31221780.
      View in: PubMed
    63. Janz S, Zhan F, Sun F, Cheng Y, Pisano M, Yang Y, Goldschmidt H, Hari P. Germline Risk Contribution to Genomic Instability in Multiple Myeloma. Front Genet. 2019; 10:424. PMID: 31139207.
      View in: PubMed
    64. Ali M, Kowkuntla S, Delloro DJ, Galambos C, Hathi D, Janz S, Shokeen M, Tripathi C, Xu H, Yuk J, Zhan F, Tomasson MH, Bates ML. Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice. Am J Physiol Regul Integr Comp Physiol. 2019 05 01; 316(5):R678-R686. PMID: 30892915.
      View in: PubMed
    65. Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. J Clin Invest. 2019 03 04; 129(4):1641-1653. PMID: 30721156.
      View in: PubMed
    66. Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer. 2018 Nov 21; 18(1):1152. PMID: 30463534.
      View in: PubMed
    67. Tomasson MH, Ali M, De Oliveira V, Xiao Q, Jethava Y, Zhan F, Fitzsimmons AM, Bates ML. Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma. Int J Mol Sci. 2018 Nov 16; 19(11). PMID: 30453544.
      View in: PubMed
    68. Hao M, Barlogie B, Tricot G, Liu L, Qiu L, Shaughnessy JD, Zhan F. Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenstr?m's Macroglobulinemia. Clin Cancer Res. 2019 01 01; 25(1):201-209. PMID: 30279229.
      View in: PubMed
    69. Franqui-Machin R, Hao M, Bai H, Gu Z, Zhan X, Habelhah H, Jethava Y, Qiu L, Frech I, Tricot G, Zhan F. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018 07 02; 128(7):2877-2893. PMID: 29863498.
      View in: PubMed
    70. Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, Seckinger A, Zhan F, Tricot G, Goldschmidt H, Yang Y, Janz S. Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. Blood Cancer J. 2018 02 15; 8(2):22. PMID: 29449574.
      View in: PubMed
    71. Zhan X, Yu W, Franqui-Machin R, Bates ML, Nadiminti K, Cao H, Amendt BA, Jethava Y, Frech I, Zhan F, Tricot G. Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma. Oncotarget. 2017 Dec 19; 8(67):111213-111224. PMID: 29340048.
      View in: PubMed
    72. Tao Y, Yang G, Yang H, Song D, Hu L, Xie B, Wang H, Gao L, Gao M, Xu H, Xu Z, Wu X, Zhang Y, Zhu W, Zhan F, Shi J. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma. Oncotarget. 2017 Apr 18; 8(16):26718-26731. PMID: 28157697.
      View in: PubMed
    73. Xia J, Xu H, Zhang X, Allamargot C, Coleman KL, Nessler R, Frech I, Tricot G, Zhan F. Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid. EBioMedicine. 2017 Apr; 18:41-49. PMID: 28229908.
      View in: PubMed
    74. Gu Z, Xia J, Xu H, Frech I, Tricot G, Zhan F. NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase. J Hematol Oncol. 2017 01 13; 10(1):17. PMID: 28086949.
      View in: PubMed
    75. Nadiminti K, Singh Abbi KK, Mott SL, Dozeman L, Tricot A, Schultz A, Behrends S, Zhan F, Tricot G. VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma. Onco Targets Ther. 2017; 10:217-226. PMID: 28123303.
      View in: PubMed
    76. Schibler J, Tomanek-Chalkley AM, Reedy JL, Zhan F, Spitz DR, Schultz MK, Goel A. Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells. PLoS One. 2016; 11(11):e0167323. PMID: 27902770.
      View in: PubMed
    77. Hao M, Zang M, Zhao L, Deng S, Xu Y, Qi F, An G, Qin Y, Sui W, Li F, Yang W, Li Z, Yi S, Zou D, Zhan F, Qiu L. Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget. 2016 Apr 12; 7(15):19589-600. PMID: 26995755.
      View in: PubMed
    78. Wang H, Xie B, Kong Y, Tao Y, Yang G, Gao M, Xu H, Zhan F, Shi J, Zhang Y, Wu X. Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3. Oncotarget. 2016 Apr 05; 7(14):18638-50. PMID: 26942564.
      View in: PubMed
    79. Gao M, Kong Y, Wang H, Xie B, Yang G, Gao L, Zhang Y, Zhan F, Dai B, Tao Y, Shi J. Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials. Tumour Biol. 2016 Aug; 37(8):11081-98. PMID: 26906553.
      View in: PubMed
    80. Ramani VC, Zhan F, He J, Barbieri P, Noseda A, Tricot G, Sanderson RD. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget. 2016 Jan 12; 7(2):1598-607. PMID: 26624982.
      View in: PubMed
    81. Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget. 2015 Dec 01; 6(38):41275-89. PMID: 26513296.
      View in: PubMed
    82. Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Oncotarget. 2015 Dec 01; 6(38):40496-506. PMID: 26415231.
      View in: PubMed
    83. Yang G, Gao M, Zhang Y, Kong Y, Gao L, Tao Y, Han Y, Wu H, Meng X, Xu H, Zhan F, Wu X, Shi J. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Oncotarget. 2015 Sep 29; 6(29):26982-94. PMID: 26323098.
      View in: PubMed
    84. Yang G, Zhang Q, Kong Y, Xie B, Gao M, Tao Y, Xu H, Zhan F, Dai B, Shi J, Wu X. Antitumor activity of fucoidan against diffuse large B cell lymphoma in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai). 2015 Nov; 47(11):925-31. PMID: 26358321.
      View in: PubMed
    85. Gao M, Yang G, Han Y, Kong Y, Wu H, Tao Y, Zhan F, Shi J, Wu X. Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015; 8(8):12202-10. PMID: 26550130.
      View in: PubMed
    86. Li Z, Li F, Yi S, Gu Z, Yu Z, Xu Y, Feng X, Liu W, Zou D, Qi J, Zhan F, Qiu L. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. BMC Cancer. 2015 Jul 29; 15:555. PMID: 26219471.
      View in: PubMed
    87. Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, Tricot G, Zhan F. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma. Clin Cancer Res. 2015 Dec 15; 21(24):5532-42. PMID: 26156395.
      View in: PubMed
    88. Zhan F, Zangari M, Qiu L. Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics. Biomed Res Int. 2015; 2015:384575. PMID: 26000289.
      View in: PubMed
    89. Li F, Hao M, Feng X, Zang M, Qin Y, Yi S, Li Z, Xu Y, Zhou L, Sui W, Deng S, Zou D, Zhan F, Qiu L. Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Leuk Res. 2015 Jul; 39(7):793-9. PMID: 25975752.
      View in: PubMed
    90. Trotter TN, Li M, Pan Q, Peker D, Rowan PD, Li J, Zhan F, Suva LJ, Javed A, Yang Y. Myeloma cell-derived Runx2 promotes myeloma progression in bone. Blood. 2015 Jun 04; 125(23):3598-608. PMID: 25862559.
      View in: PubMed
    91. Gu Z, Wang H, Xia J, Yang Y, Jin Z, Xu H, Shi J, De Domenico I, Tricot G, Zhan F. Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation. Cancer Res. 2015 Jun 01; 75(11):2211-21. PMID: 25855377.
      View in: PubMed
    92. Han SS, Tompkins VS, Son DJ, Han S, Yun H, Kamberos NL, Dehoedt CL, Gu C, Holman C, Tricot G, Zhan F, Janz S. CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma. Exp Hematol Oncol. 2015; 4:9. PMID: 25838973.
      View in: PubMed
    93. Xia J, Franqui Machin R, Gu Z, Zhan F. Role of NEK2A in human cancer and its therapeutic potentials. Biomed Res Int. 2015; 2015:862461. PMID: 25705694.
      View in: PubMed
    94. Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res. 2015 Feb 01; 75(3):594-604. PMID: 25589346.
      View in: PubMed
    95. Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget. 2014 Dec 15; 5(23):11986-97. PMID: 25230277.
      View in: PubMed
    96. Gao L, Zhan F, Shi J. [Myeloma cancer stem cells:the new target for multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2014 Dec; 35(12):1134-7. PMID: 25543715.
      View in: PubMed
    97. Salem K, McCormick ML, Wendlandt E, Zhan F, Goel A. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma. Redox Biol. 2015; 4:23-33. PMID: 25485927.
      View in: PubMed
    98. Gu Z, Zhou W, Huang J, Yang Y, Wendlandt E, Xu H, He X, Tricot G, Zhan F. Nek2 is a novel regulator of B cell development and immunological response. Biomed Res Int. 2014; 2014:621082. PMID: 25485281.
      View in: PubMed
    99. Gao M, Yang G, Tompkins VS, Gao L, Wu X, Tao Y, Hu X, Hou J, Han Y, Xu H, Zhan F, Shi J. Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials. PLoS One. 2014; 9(10):e109758. PMID: 25279718.
      View in: PubMed
    100. Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, Li F, Qi F, Zhang Y, Yang Y, Zhan F, Qiu L. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2015 Apr 15; 136(8):1835-44. PMID: 25220540.
      View in: PubMed
    101. Meng L, Carpenter K, Mollard A, Vankayalapati H, Warner SL, Sharma S, Tricot G, Zhan F, Bearss DJ. Inhibition of Nek2 by small molecules affects proteasome activity. Biomed Res Int. 2014; 2014:273180. PMID: 25313354.
      View in: PubMed
    102. Salama ME, Du S, Efimova O, Heikal NM, Wendlandt E, Toydemir RM, South S, Perkins SL, Hussong JW, Zhan F. Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities. Leuk Lymphoma. 2015 Feb; 56(2):426-33. PMID: 24913506.
      View in: PubMed
    103. Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res. 2014 Aug; 59(1-3):188-202. PMID: 24845460.
      View in: PubMed
    104. Gao M, Gao L, Yang G, Tao Y, Hou J, Xu H, Hu X, Han Y, Zhang Q, Zhan F, Wu X, Shi J. Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism. Acta Biochim Biophys Sin (Shanghai). 2014 Jul; 46(7):597-604. PMID: 24850305.
      View in: PubMed
    105. Gao M, Gao L, Yang G, Tao Y, Tompkins VS, Wu X, Xu H, Zhan F, Shi J. Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials. Int J Clin Exp Pathol. 2014; 7(6):3073-80. PMID: 25031726.
      View in: PubMed
    106. Gao M, Gao L, Tao Y, Hou J, Yang G, Wu X, Xu H, Tompkins VS, Han Y, Wu H, Zhan F, Shi J. Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells. Acta Biochim Biophys Sin (Shanghai). 2014 Jun; 46(6):484-91. PMID: 24801128.
      View in: PubMed
    107. Zou D, An G, Zhu G, Wang J, Shi L, Meng H, Xu Y, Sui W, Deng S, Zhan F, Qiu L. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias. Biol Blood Marrow Transplant. 2014 Mar; 20(3):319-25. PMID: 24296491.
      View in: PubMed
    108. An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, Sui W, Zhan F, Qiu L. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014 Feb; 99(2):353-9. PMID: 24213147.
      View in: PubMed
    109. Stessman HA, Mansoor A, Zhan F, Linden MA, Van Ness B, Baughn LB. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. PLoS One. 2013; 8(10):e77608. PMID: 24204892.
      View in: PubMed
    110. Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H, Zhou W, Zhou Y, Das S, Gu Z, Levasseur D, Zhan F, Tricot G. RARa2 expression confers myeloma stem cell features. Blood. 2013 Aug 22; 122(8):1437-47. PMID: 23847194.
      View in: PubMed
    111. Tao Y, Gao L, Wu X, Wang H, Yang G, Zhan F, Shi J. Down-regulation of 11?-hydroxysteroid dehydrogenase type 2 by bortezomib sensitizes Jurkat leukemia T cells against glucocorticoid-induced apoptosis. PLoS One. 2013; 8(6):e67067. PMID: 23826195.
      View in: PubMed
    112. Veitonm?ki N, Hansson M, Zhan F, Sundberg A, L?fstedt T, Ljungars A, Li ZC, Martinsson-Niskanen T, Zeng M, Yang Y, Danielsson L, Kovacek M, Lundqvist A, M?rtensson L, Teige I, Tricot G, Frend?us B. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15; 23(4):502-15. PMID: 23597564.
      View in: PubMed
    113. An G, Shi L, Xu Y, Zou D, Deng S, Sui W, Zhu G, Xie Z, Hao M, Sun Q, Zhan F, Qiu L. Prognostic value of high serum lactate dehydrogenase in plasma cell dyscrasias: a re-evaluation in the context of cytogenetic aberration data. Leuk Lymphoma. 2013 Nov; 54(11):2556-9. PMID: 23418896.
      View in: PubMed
    114. Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013 Jun; 12(6):1140-50. PMID: 23536725.
      View in: PubMed
    115. Brown CO, Schibler J, Fitzgerald MP, Singh N, Salem K, Zhan F, Goel A. Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma. Leuk Res. 2013 Aug; 37(8):963-9. PMID: 23537707.
      View in: PubMed
    116. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D, Tricot G, Zhan F. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013 Jan 14; 23(1):48-62. PMID: 23328480.
      View in: PubMed
    117. Zangari M, Berno T, Zhan F, Tricot G, Fink L. Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. Semin Thromb Hemost. 2012 Nov; 38(8):768-79. PMID: 23104518.
      View in: PubMed
    118. Zangari M, Terpos E, Zhan F, Tricot G. Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treat Rev. 2012 Dec; 38(8):968-80. PMID: 22226939.
      View in: PubMed
    119. Wu X, Shao Y, Tao Y, Ai G, Wei R, Meng X, Hou J, Han Y, Zhan F, Zheng J, Shi J. Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I. Biochem Biophys Res Commun. 2011 Nov 11; 415(1):187-92. PMID: 22033416.
      View in: PubMed
    120. Cruz RD, Tricot G, Zangari M, Zhan F. Progress in myeloma stem cells. Am J Blood Res. 2011; 1(2):135-45. PMID: 22432075.
      View in: PubMed
    121. Zangari M, Berno T, Zhan F, Boucher KM, Tricot G, Fink L. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. Blood Coagul Fibrinolysis. 2011 Jul; 22(5):420-3. PMID: 21537162.
      View in: PubMed
    122. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7. PMID: 21477075.
      View in: PubMed
    123. Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):228-36. PMID: 21575928.
      View in: PubMed
    124. Wu X, Shi J, Wu Y, Tao Y, Hou J, Meng X, Hu X, Han Y, Jiang W, Tang S, Zangari M, Tricot G, Zhan F. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer Biol Ther. 2010 Dec 01; 10(11):1201-14. PMID: 20953137.
      View in: PubMed
    125. Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, Esseltine D, Tricot G. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica. 2011 Feb; 96(2):333-6. PMID: 20952514.
      View in: PubMed
    126. Zangari M, Zhan F, Tricot G. Bone and paraproteinemias. Curr Opin Support Palliat Care. 2010 Sep; 4(3):195-9. PMID: 20657285.
      View in: PubMed
    127. Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G, Zhan F. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget. 2010 May; 1(1):22-33. PMID: 20930946.
      View in: PubMed
    128. Heerema-McKenney A, Waldron J, Hughes S, Zhan F, Sawyer J, Barlogie B, Shaughnessy JD. Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma. Am J Clin Pathol. 2010 Feb; 133(2):265-70. PMID: 20093236.
      View in: PubMed
    129. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010 Jan 01; 28(1):132-5. PMID: 19901114.
      View in: PubMed
    130. Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD, Zhan F. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood. 2010 Jan 07; 115(1):61-70. PMID: 19837979.
      View in: PubMed
    131. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD, Barlogie B, Yaccoby S, Afar DE. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009 Sep; 8(9):2616-24. PMID: 19723891.
      View in: PubMed
    132. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009 Oct 10; 27(29):4865-73. PMID: 19704059.
      View in: PubMed
    133. Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, Dhodapkar M, Nevins J, Barlogie B, Shaughnessy JD, Potti A. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol. 2009 Sep 01; 27(25):4197-203. PMID: 19636021.
      View in: PubMed
    134. Wang S, Tricot G, Shi L, Xiong W, Zeng Z, Xu H, Zangari M, Barlogie B, Shaughnessy JD, Zhan F. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood. 2009 Jul 16; 114(3):600-7. PMID: 19458357.
      View in: PubMed
    135. Brenne AT, Fagerli UM, Shaughnessy JD, V?tsveen TK, R? TB, Hella H, Zhan F, Barlogie B, Sundan A, B?rset M, Waage A. High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis. Eur J Haematol. 2009 May; 82(5):354-63. PMID: 19191868.
      View in: PubMed
    136. Burington B, Barlogie B, Zhan F, Crowley J, Shaughnessy JD. Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res. 2008 Aug 01; 14(15):4821-9. PMID: 18676754.
      View in: PubMed
    137. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008 May 01; 14(9):2775-84. PMID: 18451245.
      View in: PubMed
    138. Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, Chen L, Barlogie B, Shaughnessy JD, Zhan F. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008 Nov 15; 112(10):4235-46. PMID: 18337559.
      View in: PubMed
    139. Zhan F, Barlogie B, Mulligan G, Shaughnessy JD, Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood. 2008 Jan 15; 111(2):968-9. PMID: 18182586.
      View in: PubMed
    140. Haessler J, Shaughnessy JD, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G, Barlogie B. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res. 2007 Dec 01; 13(23):7073-9. PMID: 18056185.
      View in: PubMed
    141. Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, Thuro B, Melenhorst J, Barrett J, Shaughnessy J, Old LJ, Barlogie B, Brichard VG, van Rhee F. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother. 2007 Nov-Dec; 30(8):847-54. PMID: 18049337.
      View in: PubMed
    142. Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD, Sundan A, B?rset M. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood. 2008 Jan 15; 111(2):806-15. PMID: 17934070.
      View in: PubMed
    143. Prasad HK, Zhan F, Shaughnessy J. Smoldering multiple myeloma. N Engl J Med. 2007 Sep 06; 357(10):1048; author reply 1049-50. PMID: 17804853.
      View in: PubMed
    144. Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol. 2007 Sep; 138(6):802-11. PMID: 17760811.
      View in: PubMed
    145. Park ES, Shaughnessy JD, Gupta S, Wang H, Lee JS, Woo HG, Zhan F, Owens JD, Potter M, Janz S, Mushinski JF. Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics. 2007 Aug 31; 8:302. PMID: 17764563.
      View in: PubMed
    146. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl WM, Staudt LM. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007 Aug; 12(2):115-30. PMID: 17692804.
      View in: PubMed
    147. Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD, Epstein J, Kwak LW, Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 Sep 01; 110(5):1587-94. PMID: 17515399.
      View in: PubMed
    148. Zhan FH, Barlogie B, John D S. Gene expression profiling defines a high-risk entity of multiple myeloma. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007 Apr; 32(2):191-203. PMID: 17478923.
      View in: PubMed
    149. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD, Sawyer J, Li JP, Zcharia E, Vlodavsky I, Sanderson RD. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem. 2007 May 04; 282(18):13326-33. PMID: 17347152.
      View in: PubMed
    150. Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B, Shaughnessy JD. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007 Jun 01; 109(11):4995-5001. PMID: 17303695.
      View in: PubMed
    151. Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood. 2007 May 15; 109(10):4470-7. PMID: 17255354.
      View in: PubMed
    152. Park ES, Lee JS, Woo HG, Zhan F, Shih JH, Shaughnessy JD, Frederic Mushinski J. Heterologous tissue culture expression signature predicts human breast cancer prognosis. PLoS One. 2007 Jan 03; 2(1):e145. PMID: 17206280.
      View in: PubMed
    153. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007 Apr 15; 109(8):3177-88. PMID: 17185464.
      View in: PubMed
    154. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007 Mar 15; 109(6):2276-84. PMID: 17105813.
      View in: PubMed
    155. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007 Mar 01; 109(5):2106-11. PMID: 17068150.
      View in: PubMed
    156. Dib A, Peterson TR, Raducha-Grace L, Zingone A, Zhan F, Hanamura I, Barlogie B, Shaughnessy J, Kuehl WM. Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. Cell Div. 2006 Oct 18; 1:23. PMID: 17049078.
      View in: PubMed
    157. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007 Feb 15; 109(4):1692-700. PMID: 17023574.
      View in: PubMed
    158. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD. The molecular classification of multiple myeloma. Blood. 2006 Sep 15; 108(6):2020-8. PMID: 16728703.
      View in: PubMed
    159. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006 Sep 01; 108(5):1724-32. PMID: 16705089.
      View in: PubMed
    160. Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J, Yaccoby S. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol. 2006 Apr; 133(1):83-92. PMID: 16512833.
      View in: PubMed
    161. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD, Brennan C, Depinho RA. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006 Apr; 9(4):313-25. PMID: 16616336.
      View in: PubMed
    162. Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, Hanamura I, Huang Y, Ogura T, Takahashi S, Ueda R, Barlogie B, Shaughnessy J, Esumi H. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene. 2005 Oct 20; 24(46):6936-44. PMID: 16044163.
      View in: PubMed
    163. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005 Jul 01; 106(1):296-303. PMID: 15755896.
      View in: PubMed
    164. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005 May 15; 105(10):3939-44. PMID: 15671442.
      View in: PubMed
    165. Santin AD, Zhan F, Bignotti E, Siegel ER, Can? S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005 Jan 20; 331(2):269-91. PMID: 15629771.
      View in: PubMed
    166. Shaughnessy J, Zhan F, Barlogie B, Stewart AK. Gene expression profiling and multiple myeloma. Best Pract Res Clin Haematol. 2005; 18(4):537-52. PMID: 16026736.
      View in: PubMed
    167. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004 Oct 20; 112(1):14-25. PMID: 15305371.
      View in: PubMed
    168. Lin P, Mahdavy M, Zhan F, Zhang HZ, Katz RL, Shaughnessy JD. Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol. 2004 Oct; 17(10):1217-22. PMID: 15195108.
      View in: PubMed
    169. Hardin J, Waddell M, Page CD, Zhan F, Barlogie B, Shaughnessy J, Crowley JJ. Evaluation of multiple models to distinguish closely related forms of disease using DNA microarray data: an application to multiple myeloma. Stat Appl Genet Mol Biol. 2004; 3:Article10. PMID: 16646788.
      View in: PubMed
    170. Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, Strachan E, Crainie M, Walker R, Belch AR, Pilarski LM, Barlogie B, Shaughnessy J, Reiman T. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood. 2004 Aug 15; 104(4):1151-8. PMID: 15105292.
      View in: PubMed
    171. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003 Dec 25; 349(26):2483-94. PMID: 14695408.
      View in: PubMed
    172. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res. 2003 Dec 15; 63(24):8749-56. PMID: 14695190.
      View in: PubMed
    173. Zhan F, Barlogie B, Shaughnessy J. Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling. Semin Hematol. 2003 Oct; 40(4):308-20. PMID: 14582081.
      View in: PubMed
    174. Zent CS, Zhan F, Schichman SA, Bumm KH, Lin P, Chen JB, Shaughnessy JD. The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. Leuk Res. 2003 Sep; 27(9):765-74. PMID: 12804633.
      View in: PubMed
    175. Guikema JE, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH, Bekkema R, Smit JW, Zhan F, Shaughnessy J, Bos NA. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol. 2003 Apr; 121(1):36-43. PMID: 12670329.
      View in: PubMed
    176. Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy J. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood. 2003 Jul 15; 102(2):592-600. PMID: 12663452.
      View in: PubMed
    177. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Tricot G, Crowley J, Barlogie B. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003 May 15; 101(10):3849-56. PMID: 12531801.
      View in: PubMed
    178. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood. 2003 Mar 15; 101(6):2374-6. PMID: 12433679.
      View in: PubMed
    179. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood. 2003 Feb 01; 101(3):1128-40. PMID: 12393520.
      View in: PubMed
    180. Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V, R?me T, Legouffe E, Rossi JF, Shaughnessy J, ?rntoft TF, Klein B. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood. 2002 Aug 15; 100(4):1113-22. PMID: 12149187.
      View in: PubMed
    181. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002 Mar 01; 99(5):1745-57. PMID: 11861292.
      View in: PubMed
    182. Bumm K, Zheng M, Bailey C, Zhan F, Chiriva-Internati M, Eddlemon P, Terry J, Barlogie B, Shaughnessy JD. CGO: utilizing and integrating gene expression microarray data in clinical research and data management. Bioinformatics. 2002 Feb; 18(2):327-8. PMID: 11847084.
      View in: PubMed
    Zhan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (553) concept(s)
    _
    Co-Authors Expand Description
    See all (37) people
    _
    Similar People Expand Description
    See all (36) people
    _
    Same Department Expand Description
    Search Department